Free Trial

Evofem Biosciences (EVFM) Competitors

$0.01
0.00 (0.00%)
(As of 05/24/2024 ET)

EVFM vs. CMRA, VRPX, SPRC, SBFM, BLPH, HSTO, BPTH, ALLR, SXTC, and NBSE

Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Comera Life Sciences (CMRA), Virpax Pharmaceuticals (VRPX), SciSparc (SPRC), Sunshine Biopharma (SBFM), Bellerophon Therapeutics (BLPH), Histogen (HSTO), Bio-Path (BPTH), Allarity Therapeutics (ALLR), China SXT Pharmaceuticals (SXTC), and NeuBase Therapeutics (NBSE). These companies are all part of the "pharmaceutical preparations" industry.

Evofem Biosciences vs.

Evofem Biosciences (NASDAQ:EVFM) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.

Evofem Biosciences received 262 more outperform votes than Comera Life Sciences when rated by MarketBeat users.

CompanyUnderperformOutperform
Evofem BiosciencesOutperform Votes
262
69.50%
Underperform Votes
115
30.50%
Comera Life SciencesN/AN/A

In the previous week, Evofem Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Evofem Biosciences Neutral
Comera Life Sciences Neutral

Evofem Biosciences has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.

0.2% of Evofem Biosciences shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evofem Biosciences has higher revenue and earnings than Comera Life Sciences. Comera Life Sciences is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$18.22M0.06$52.98M-$5.930.00
Comera Life Sciences$630K1.43-$18M-$0.49-0.06

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Comera Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Evofem Biosciences has a net margin of 315.54% compared to Comera Life Sciences' net margin of -904.00%. Comera Life Sciences' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences315.54% -81.10% 437.75%
Comera Life Sciences -904.00%N/A -297.91%

Summary

Evofem Biosciences beats Comera Life Sciences on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVFM vs. The Competition

MetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.02M$6.81B$5.20B$8.06B
Dividend YieldN/A2.67%2.83%3.93%
P/E Ratio0.0021.27152.1518.19
Price / Sales0.06259.912,464.4379.80
Price / Cash0.0136.7936.3031.61
Price / Book-0.015.865.444.60
Net Income$52.98M$132.39M$106.24M$214.07M
7 Day PerformanceN/A-2.40%-1.33%-1.08%
1 Month PerformanceN/A1.64%2.76%3.20%
1 Year PerformanceN/A-6.49%3.39%7.84%

Evofem Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
0 of 5 stars
$0.03
flat
N/A-95.3%$899,000.00$630,000.00-0.0612Gap Up
VRPX
Virpax Pharmaceuticals
0 of 5 stars
$0.74
-3.9%
N/A-91.0%$867,000.00N/A0.007Analyst Forecast
News Coverage
Gap Down
High Trading Volume
SPRC
SciSparc
0 of 5 stars
$1.18
-3.3%
N/A-92.6%$838,000.00$2.88M0.003Positive News
Gap Up
SBFM
Sunshine Biopharma
2.7627 of 5 stars
$0.81
-17.4%
$260.00
+32,174.1%
-98.9%$798,000.00$24.09M-0.0444Gap Down
High Trading Volume
BLPH
Bellerophon Therapeutics
1.0911 of 5 stars
$0.06
flat
$2.00
+3,101.0%
-99.3%$764,000.00N/A-0.0718Analyst Forecast
News Coverage
Gap Down
HSTO
Histogen
0 of 5 stars
$0.17
flat
N/A-81.9%$726,000.00$19,000.00-0.067Gap Up
BPTH
Bio-Path
1.8047 of 5 stars
$2.00
-7.8%
$40.00
+1,900.0%
-94.1%$1.36MN/A0.0010News Coverage
ALLR
Allarity Therapeutics
0.0876 of 5 stars
$0.58
-7.9%
N/A-99.7%$1.38MN/A0.005Gap Down
SXTC
China SXT Pharmaceuticals
0 of 5 stars
$1.14
-5.8%
N/A-82.5%$524,000.00$1.97M0.0078Positive News
Gap Down
NBSE
NeuBase Therapeutics
0 of 5 stars
$0.38
flat
N/AN/A$1.43MN/A-0.0537

Related Companies and Tools

This page (NASDAQ:EVFM) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners